Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 6/20 | 0.63 |
| ▸ | CYP26A1 | O43174 | 9/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | NAMPT | P43490 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.37 |
| ▸ | ESR1 | P03372 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2363089 | 0.80 | NR3C1 (0.46) | NR3C1CYP26A1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL12417576 | 0.78 | NR3C1 (0.53) | NR3C1NAMPTALDH1A1TDP1TBXAS1 | |
| SCHEMBL14826292 | 0.78 | KCNN4 (0.50) | NR3C1CYP26A1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL12378880 | 0.78 | NR3C1 (1.00) | NR3C1 | |
| SCHEMBL12378918 | 0.78 | NR3C1 (0.74) | NR3C1 | |
| SCHEMBL28672348 | 0.76 | CYP26A1 (0.44) | NR3C1CYP26A1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL1363885 | 0.73 | KMT2A (0.46) | NR3C1CYP26A1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL2363471 | 0.73 | NR3C1 (0.68) | NR3C1CYP26A1 | |
| SCHEMBL754412 | 0.72 | NR3C1 (0.43) | NR3C1CYP26A1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL2901478 | 0.70 | POLB (0.57) | CYP26A1CYP1A2CYP3A4CYP2D6CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7994190-B2 | Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-08-09 | — | — | US | disclosed |
| US-20100190820-A1 | MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-kB ACTIVITY AND USE THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2010-07-29 | — | — | US | disclosed |
| WO-2008057855-A2 | HETEROCYCLIC COMPOUNDS AS MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-I, AND/OR NP-KAPPA-B ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-05-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100190820-A1 | MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-kB ACTIVITY AND USE THEREOF | NR0B1, NR3C1, NFRKB | NR3C1 2/4885CYP26A1 1326/4885CYP1A2 1420/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.